Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Francis Payumo"'
Autor:
Frank Siebenhaar, Jason Gotlib, Michael W. Deininger, Daniel J. DeAngelo, Francis Payumo, George Mensing, Hina Jolin, Jessica Sachs, Tracy I. George
Publikováno v:
Blood. 138:3642-3642
Systemic mastocytosis (SM) is characterized by mast cell infiltration of ≥ 1 extracutaneous organs and encompasses a spectrum of diagnoses that can range from a non-advanced to advanced disease (Shomali et al, 2018). There are two nonadvanced varia
Autor:
Hina Jolin, Prithviraj Bose, Michael W. Deininger, Vinod Pullarkat, Jessica Sachs, Jason Gotlib, Daniel J. DeAngelo, Tsewang Tashi, Tracy I. George, Amanda Pilla, Francis Payumo
Publikováno v:
Blood. 138:3636-3636
Systemic mastocytosis (SM) is characterized by excessive accumulation of mast cells in bone marrow and other extracutaneous tissues encompassing a spectrum of variants ranging from non-advanced to advanced disease (Shomali et al, 2018). Advanced syst
Autor:
Ann Ranger, Jonathon B. Cohen, Francis Payumo, Veronika Bachanova, Patricia L. Harris, Luke P. Akard, Jason R. Westin, Ian W. Flinn, Samantha Jaglowski, Jessica Sachs
Publikováno v:
Blood. 134:1587-1587
Background: The Antibody-Coupled T-cell Receptor (ACTR) platform is an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immu
Autor:
Matthew McKinney, Francis Payumo, Ann Ranger, Samantha Jaglowski, Jessica Sachs, Patrick J. Stiff, Iris Isufi, Luke P. Akard, Patricia Harris, Javier Munoz
Publikováno v:
Blood. 134:244-244
Background: The Antibody-Coupled T-cell Receptor (ACTR) platform is an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor immu
Autor:
Ian W. Flinn, Francis Payumo, Veronika Bachanova, Samantha Jaglowski, Greg Motz, Patricia L. Harris, Luke P. Akard, Ann Ranger, Michael J. Vasconcelles, Jonathon B. Cohen
Publikováno v:
Blood. 132:2966-2966
Background: Recent regulatory approvals of two CD19-targeted chimeric antigen receptor (CAR)-expressing autologous T lymphocyte therapies provide compelling evidence of the clinical potential of re-engineering T cells to specifically attack tumor cel